US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
The drug received standard U.S. approval in 2023 after showing it slowed cognitive decline in patients with the brain-wasting ...
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's ...